Immunic Will Develop IMU-856, Promising IBD Therapy

Immunic Will Develop IMU-856, Promising IBD Therapy
Immunic earned the exclusive rights to develop a group of innovative disease-modifying therapies, now renamed IMU-856, for inflammatory bowel disease (IBD). IMU-856, originally developed by Daiichi Sankyo, is an oral small molecule whose target is yet undisclosed but is a key player in the onset and relapse of both forms of IBD, ulcerative colitis and Crohn’s disease. “We are very excited that Daiichi Sankyo selected the Immunic team as their partner to take over the future development of this unique drug candidate,” Daniel Vitt, CEO of Immunic, said in a
Subscribe or to access all post and page content.